股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 滬港聯合控股有限公司 呈交日期: 2025年12月1日 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01001 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.1 HKD | | 100,000,000 | 本 ...

Company Overview - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - The company is a leading developer of innovative differentiated small molecule inhibitors targeting autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3] Product Pipeline - Key products include LNK01001, a highly selective second-generation JAK1 inhibitor, and LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor, both targeting autoimmune and inflammatory diseases [3] - LNK01006 is a cutting-edge, highly selective allosteric TYK2 inhibitor designed to penetrate the central nervous system, targeting related diseases [3] - The company has developed the proprietary IsoNova protein degradation platform, which enhances target selectivity and reduces off-target effects, expanding the range of degradable targets [3][4] Market Potential - The global JAK inhibitor market is projected to grow from $5.5 billion in 2019 to $13.9 billion in 2024, with expectations to reach $25.6 billion by 2028 and $40.8 billion by 2033 [6][16] - In China, the JAK inhibitor market is expected to expand from RMB 400 million in 2019 to RMB 3.8 billion in 2024, with forecasts of RMB 17.1 billion by 2028 and RMB 46.5 billion by 2033 [6][16] Clinical Development - As of the last feasible date, the company has 53 issued patents and 106 pending patent applications, with 34 issued patents and 45 pending applications related to its core and key products [7] - LNK01001 is currently undergoing multiple Phase III clinical trials, with new drug application stages expected in 2026 and 2027 for various indications [7] - LNK01004 has completed Phase II trials in China and plans to initiate Phase III trials in mid-2027 [7] Financial Performance - The company reported other income of RMB 20.57 million in 2023, RMB 16.98 million in 2024, and RMB 54.78 million for the nine months ending September 30, 2025 [9] - Annual losses were approximately RMB 260 million in 2023, RMB 312 million in 2024, and RMB 145 million for the nine months ending September 30, 2025 [10] - Research and development expenses were RMB 186 million in 2023, RMB 223 million in 2024, and RMB 121 million for the nine months ending September 30, 2025 [11] Industry Overview - The global market for autoimmune and inflammatory disease drugs grew from $133 billion in 2019 to $160.8 billion in 2024, with a compound annual growth rate (CAGR) of 3.9% [13] - The Chinese market for autoimmune and inflammatory disease drugs is expected to grow from RMB 42.7 billion in 2019 to RMB 66.5 billion in 2024, with a CAGR of 9.3% [13][14]

Company Overview - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - The company is a leading developer of innovative small molecule inhibitors for autoimmune and inflammatory diseases, focusing on the JAK-STAT signaling pathway [3] Product Pipeline - The core products include LNK01001, a highly selective second-generation JAK1 inhibitor; LNK01004, a potential first-in-class third-generation soft pan-JAK inhibitor; and LNK01006, a cutting-edge TYK2 inhibitor targeting central nervous system diseases [3][4] - The company has developed an innovative proprietary IsoNova protein degradation platform, enhancing target selectivity and reducing off-target effects, with potential applications beyond autoimmune diseases to oncology and neurodegenerative diseases [4] Market Potential - The global JAK inhibitor market is projected to grow from $5.5 billion in 2019 to $13.9 billion by 2024, with expectations to reach $25.6 billion by 2028 and $40.8 billion by 2033 [6][16] - In China, the JAK inhibitor market is expected to expand from RMB 400 million in 2019 to RMB 3.8 billion by 2024, with forecasts of RMB 17.1 billion by 2028 and RMB 46.5 billion by 2033 [6][16] Clinical Development - As of the last feasible date, the company has advanced its core candidates LNK01001 and LNK01004 into clinical stages, with LNK01001 undergoing multiple Phase III trials and LNK01004 having completed Phase II trials in China [7][8] - The company aims to maximize patient efficacy and safety through the development of innovative candidates, with several preclinical candidates also in the pipeline [8] Financial Performance - The company reported other income of RMB 20.57 million, RMB 16.98 million, and RMB 54.78 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual losses for the same periods were approximately RMB 260 million, RMB 312 million, and RMB 145 million [10] - Research and development expenditures were approximately RMB 186 million, RMB 223 million, and RMB 121 million for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [11] Industry Overview - The global market for autoimmune and inflammatory disease drugs has grown from $133 billion in 2019 to $160.8 billion in 2024, with a projected CAGR of 3.9% [12] - The Chinese market for autoimmune and inflammatory disease drugs is expected to grow from RMB 42.7 billion in 2019 to RMB 66.5 billion by 2024, with a CAGR of 9.3% [13][14]

Performance Summary - Virginie (02199.HK) reported revenue of HKD 3.84 billion for the six months ending September 30, 2025, a decrease of 3.45% year-on-year; net profit increased by 114.25% to HKD 145 million [1] - Huagang United (01001.HK) achieved revenue of HKD 1.023 billion, up 3.34% year-on-year; profit decreased by 3.64% to HKD 52.9 million [1] - Disen Creation (00113.HK) reported revenue of HKD 973 million, a year-on-year increase of 1.2%; net profit rose by 14.02% to HKD 150 million [1] - Sanhe Construction Group (03822.HK) generated revenue of HKD 470 million from customer contracts, a 20.8% increase year-on-year; net profit surged by 1364.7% to HKD 47.41 million [1] - Bojun Education (01758.HK) reported revenue of HKD 379 million for the year ending August 31, 2025, a decrease of 11.9%; losses increased by 227.6% to HKD 130 million [1] - Jiahua Holdings (00064.HK) reported revenue of HKD 172 million, down 21.01% year-on-year; profit increased by 57.59% to HKD 49.51 million [2] - Tiande Real Estate (00266.HK) reported revenue of HKD 152 million, a decrease of 2.5%; losses narrowed by 72.9% to HKD 75.43 million [3] - Kairun International Hotel (00105.HK) reported revenue of HKD 148 million, down 2.34%; losses decreased by 69.77% to HKD 148 million [4] - Safe Warehouse (00237.HK) reported revenue of HKD 84.1 million, down 9.97%; the company recorded a loss of HKD 17.56 million, shifting from profit to loss [4] Company News - Xinchen Power (01148.HK) established a strategic alliance with Sichuan Hongpeng Aerospace Equipment Intelligent Manufacturing in the field of aviation piston engines [5] - Qingdao Beer Co., Ltd. (00168.HK) plans to engage in wealth management investment activities with a maximum single-day balance of RMB 10 billion over the next 12 months [5] - Junshi Biosciences (01877.HK) plans to use up to RMB 2.4 billion of temporarily idle raised funds for cash management [5] - China Anshun Energy (02399.HK) signed a memorandum of understanding with Guo Heng for further investment and participation in energy-related projects [6] - Yanzhou Coal Mining (01171.HK) subsidiary plans to acquire 100% equity of a high-end support company for HKD 345 million [7] - Beijing Qingniao Huanyu (08095.HK) intends to invest approximately HKD 130 million to acquire the remaining 30% equity of Shanghai Shengjin Venture Capital Co., Ltd., focusing on new materials, energy conservation, and high-end equipment manufacturing [7] Financing and Buyback Activities - China Smart Technology (00464.HK) completed the issuance of a total of 11.7 million shares, raising approximately HKD 10.3 million [8] - Tencent Holdings (00700.HK) repurchased 1.036 million shares for HKD 636 million, with repurchase prices ranging from HKD 609 to HKD 620 [9] - China Petroleum & Chemical Corporation (00386.HK) repurchased 9.01 million shares for HKD 40.2765 million, with repurchase prices between HKD 4.42 and HKD 4.52 [10] - China Feihe (06186.HK) repurchased 4 million shares for HKD 16.6763 million, with repurchase prices ranging from HKD 4.12 to HKD 4.23 [10]

Core Viewpoint - The company reported a stable revenue growth of 3.3% year-on-year, driven by record production in its steel processing value-added business, which offset the impact of declining average steel prices [1] Financial Performance - For the six months ending September 30, 2025, the company's revenue increased from approximately 989.7 million HKD to about 1,022.8 million HKD [1] - The profit for the period was approximately 50.4 million HKD, compared to about 50.1 million HKD in the previous fiscal year [1] - The basic earnings per share for the period were 8.31 HKD cents, slightly down from 8.60 HKD cents in the same period last year [1]

Core Viewpoint - The company reported a revenue of HKD 1.023 billion for the six months ending September 30, 2025, reflecting a year-on-year increase of 3.34% despite a decline in average steel prices [1] Financial Performance - Revenue increased primarily due to record-high production levels in the steel processing value-added business, which effectively offset the impact of declining average steel prices [1] - The profit attributable to the company's owners was HKD 52.9 million, representing a year-on-year decrease of 3.64% [1] - Basic earnings per share were HKD 0.0831, and an interim dividend of HKD 0.02 per share was declared [1]

智通财经APP讯，沪港联合(01001)发布公告，将于2026年1月8日派发截至2025年9月30日止6个月的中期 股息每股0.02港元。 ...

第 1 頁 共 2 頁 v 1.1.1 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括姚祖輝先生及劉子超先生(為執行董事)；黃桂新女士(為非執行董事)；楊榮燊先生、李引泉先生及章曼 琪女士(為獨立非執行董事)。 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 滬港聯合控股有限公司 | | 股份代號 | 01001 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二五年九月三十日止六個月之中期股息 | | | 公告日期 | 2025年11月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | ...

HONG KONG SHANGHAI ALLIANCE HOLDINGS LIMITED 滬港聯合控股有限公司 （於百慕達註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 （股份代號：1001） 截至二零二五年九月三十日止六個月之 中期業績公告 滬港聯合控股有限公司（「本公司」）之董事會（「董事會」）謹此宣佈本公司及其附屬公司（統稱「本集 團」）截至二零二五年九月三十日止六個月（「本期間」）之未經審核簡明綜合中期業績。 財務摘要 截至二零二五年九月三十日止六個月 | | 二零二五年 | 二零二四年 | 變動 | | --- | --- | --- | --- | | | 百萬港元 | 百萬港元 | | | 收入 | 1,022.8 | 989.7 | +3.3% | | 毛利 | 167.1 | 168.2 | -0.6% | | 經營溢利 | 87.1 | 84.5 | +3.1% | | 期內溢利 | 50.4 | 50.1 ...

Group 1 - The company, Huagang United (01001.HK), announced that it will hold a board meeting on November 27, 2025, to approve the publication of its interim results for the six months ending September 30, 2025 [1] - The board meeting will also consider the distribution of an interim dividend, if applicable [1]